Bladder cancer is the 8th most common cancer with 74,000 new cases in the United States in 2015. Non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases. Transurethral resection and intravesical treatments remain the main treatment modality.
Up to 31-78% of cases recur, hence the need for intensive treatment and surveillance protocols which makes bladder cancer one of the most expensive cancers to manage. The purpose of this review is to compare contemporary guidelines from Europe, (European Association of Urology), the United States (National Comprehensive Cancer Network), the United Kingdom (National Institute for Health and Care Excellence), Japan (Japanese Urological Association) and the International Consultation on Bladder Cancer (ICUD). We compare and contrast the different guidelines and the evidence on which their recommendations are based.
Cancer treatment reviews. 2016 May 10 [Epub ahead of print]
Wei Shen Tan, Simon Rodney, Benjamin Lamb, Mark Feneley, John Kelly
Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London WC1E 6AU, UK; Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK. Electronic address: ., Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London WC1E 6AU, UK; Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK., Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK., Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK., Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London WC1E 6AU, UK; Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK.